{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+and+Metastatic+Breast+Cancer",
    "query": {
      "condition": "Advanced and Metastatic Breast Cancer"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 863,
    "total_pages": 87,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+and+Metastatic+Breast+Cancer&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T11:34:17.884Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06625775",
      "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Metastatic Breast Cancer",
        "Advanced Breast Cancer",
        "HER2 Mutation-Related Tumors",
        "HER2-positive Metastatic Breast Cancer",
        "KRAS Mutant Metastatic Colorectal Cancer",
        "Metastatic Lung Cancer",
        "Metastatic Colorectal Cancer",
        "Advanced Lung Cancer",
        "HR-positive, HER2-negative Advanced Breast Cancer",
        "HER2-positive Advanced Breast Cancer"
      ],
      "interventions": [
        {
          "name": "BBO-10203",
          "type": "DRUG"
        },
        {
          "name": "Trastuzumab",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Ribociclib",
          "type": "DRUG"
        },
        {
          "name": "FOLFOX",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 392,
      "start_date": "2024-10-29",
      "completion_date": "2028-11",
      "has_results": false,
      "last_update_posted_date": "2026-06-23",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 19,
      "location_summary": "Duarte, California • Los Angeles, California • San Diego, California + 13 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06625775"
    },
    {
      "nct_id": "NCT01183663",
      "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancers"
      ],
      "interventions": [
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Sorafenib",
          "type": "DRUG"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        },
        {
          "name": "5-fluorouracil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 180,
      "start_date": "2010-08",
      "completion_date": "2016-05",
      "has_results": false,
      "last_update_posted_date": "2016-06-03",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01183663"
    },
    {
      "nct_id": "NCT01552434",
      "title": "Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Neoplasm",
        "Castleman Disease",
        "Digestive System Carcinoma",
        "Erdheim-Chester Disease",
        "Lip and Oral Cavity Carcinoma",
        "Lymphangioleiomyomatosis",
        "Malignant Endocrine Neoplasm",
        "Malignant Female Reproductive System Neoplasm",
        "Malignant Male Reproductive System Neoplasm",
        "Malignant Neoplasm",
        "Malignant Respiratory Tract Neoplasm",
        "Malignant Thoracic Neoplasm",
        "Malignant Urinary System Neoplasm",
        "Mesothelial Neoplasm",
        "Metastatic Malignant Neoplasm",
        "Metastatic Urothelial Carcinoma",
        "Neurofibromatosis Type 2",
        "Recurrent Adult Soft Tissue Sarcoma",
        "Recurrent Breast Carcinoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Digestive System Carcinoma",
        "Recurrent Female Reproductive System Carcinoma",
        "Recurrent Male Reproductive System Carcinoma",
        "Recurrent Malignant Neoplasm",
        "Recurrent Pharyngeal Carcinoma",
        "Recurrent Thyroid Gland Carcinoma",
        "Refractory Malignant Neoplasm",
        "Soft Tissue Neoplasm",
        "Stage III Breast Cancer AJCC v7",
        "Stage III Pharyngeal Cancer",
        "Stage IIIA Breast Cancer AJCC v7",
        "Stage IIIB Breast Cancer AJCC v7",
        "Stage IIIC Breast Cancer AJCC v7",
        "Stage IV Breast Cancer AJCC v6 and v7",
        "Stage IV Pharyngeal Cancer",
        "Stage IVA Pharyngeal Cancer",
        "Stage IVB Pharyngeal Cancer",
        "Stage IVC Pharyngeal Cancer",
        "Thyroid Gland Neoplasm"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "Valproic Acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 154,
      "start_date": "2012-10-16",
      "completion_date": "2026-05-08",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01552434"
    },
    {
      "nct_id": "NCT00005807",
      "title": "Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "BMS-247550",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Albert Einstein College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2000-07",
      "completion_date": "2004-08",
      "has_results": false,
      "last_update_posted_date": "2018-10-09",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 2,
      "location_summary": "New York, New York • The Bronx, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00005807"
    },
    {
      "nct_id": "NCT05864144",
      "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor, Adult",
        "Advanced Solid Tumor",
        "Head and Neck Cancer",
        "Breast Cancer",
        "Colon Cancer",
        "Pancreatic Cancer",
        "Gastric Cancer",
        "Esophageal Cancer",
        "Prostate Cancer",
        "Uterine Cancer",
        "Cervix Cancer",
        "Ovarian Cancer",
        "Kidney Cancer",
        "Bladder Cancer",
        "Thyroid Cancer",
        "Melanoma",
        "Sarcoma",
        "Advanced Cancer",
        "Metastatic Cancer",
        "Refractory Cancer",
        "Non Small Cell Lung Cancer",
        "Merkel Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "SNS-101 (anti-VISTA)",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sensei Biotherapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 98,
      "start_date": "2023-05-31",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2025-08-15",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Louisville, Kentucky + 7 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05864144"
    },
    {
      "nct_id": "NCT03207867",
      "title": "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "NSCLC, Non Small Cell Lung Cancer",
        "RCC, Renal Cell Cancer",
        "Pancreatic Cancer",
        "Urothelial Cancer",
        "Head and Neck Cancer",
        "DLBCL, Diffused Large B Cell Lymphoma",
        "MSS, Microsatellite Stable Colon Cancer",
        "TNBC, Triple Negative Breast Cancer",
        "Melanoma",
        "mCRPC, Metastatic Castration Resistant Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "NIR178",
          "type": "DRUG"
        },
        {
          "name": "PDR001",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 315,
      "start_date": "2017-08-28",
      "completion_date": "2023-02-14",
      "has_results": true,
      "last_update_posted_date": "2024-10-09",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 5,
      "location_summary": "Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03207867"
    },
    {
      "nct_id": "NCT02046421",
      "title": "Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Male Breast Cancer",
        "Recurrent Breast Cancer",
        "Recurrent Fallopian Tube Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Recurrent Primary Peritoneal Cavity Cancer",
        "Stage IIIB Breast Cancer",
        "Stage IIIC Breast Cancer",
        "Stage IV Breast Cancer"
      ],
      "interventions": [
        {
          "name": "mifepristone",
          "type": "DRUG"
        },
        {
          "name": "carboplatin",
          "type": "DRUG"
        },
        {
          "name": "gemcitabine hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2013-11",
      "completion_date": "2018-05",
      "has_results": false,
      "last_update_posted_date": "2018-09-11",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 2,
      "location_summary": "Chicago, Illinois • Evanston, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Evanston",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02046421"
    },
    {
      "nct_id": "NCT04975308",
      "title": "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Neoplasms",
        "Neoplasm Metastasis"
      ],
      "interventions": [
        {
          "name": "Imlunestrant",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Fulvestrant",
          "type": "DRUG"
        },
        {
          "name": "Abemaciclib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 874,
      "start_date": "2021-10-04",
      "completion_date": "2027-08",
      "has_results": true,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 48,
      "location_summary": "Chandler, Arizona • Gilbert, Arizona • Greenbrae, California + 29 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Greenbrae",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04975308"
    },
    {
      "nct_id": "NCT02124148",
      "title": "A Study of Prexasertib (LY2606368) With Chemotherapy or Targeted Agents in Participants With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasm Metastasis",
        "Colorectal Neoplasms",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Prexasertib",
          "type": "DRUG"
        },
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "G-CSF",
          "type": "DRUG"
        },
        {
          "name": "Pemetrexed",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "LY3023414",
          "type": "DRUG"
        },
        {
          "name": "Leucovorin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2014-06-18",
      "completion_date": "2020-02-13",
      "has_results": false,
      "last_update_posted_date": "2020-04-01",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 5,
      "location_summary": "Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more",
      "locations": [
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02124148"
    },
    {
      "nct_id": "NCT05382299",
      "title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Triple Negative Breast Cancer",
        "PD-L1 Negative"
      ],
      "interventions": [
        {
          "name": "Sacituzumab Govitecan-hziy",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "nab-Paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 623,
      "start_date": "2022-07-20",
      "completion_date": "2028-07",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-07-24T11:34:17.884Z",
      "location_count": 130,
      "location_summary": "Tucson, Arizona • Burbank, California • La Jolla, California + 92 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05382299"
    }
  ]
}